Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Healionics Corporation is raising $10,181,048.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mike Connolly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Healionics Corporation

Healionics is a clinical-stage company addressing the critical need for improved means of dialysis access in patients with kidney failure. Our STARgraft vascular graft (artificial blood vessel) resists the problems of occlusion and infection suffered by current grafts. We also have an exciting product pipeline based on our platform STAR biomaterial which, given its unique ability to prevent both scarring and infection, can enable new types of implantable devices and improve the performance of many existing ones. The company has 33 patents issued or pending.

To learn more about Healionics Corporation, visit http://healionics.com/

Contact:
Mike Connolly, Chief Executive Officer
206-432-9060
mikec@healionics.com
https://www.linkedin.com/in/mikeconnolly1981/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved